Gyre Therapeutics, Inc.

US$4.76As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:GYREHealthcare
Country USA
PE (Fwd) •••
TSR 3Y CAGR (10.83%)
Div yield —
ROE (17.17%)
Biotechnology
Beta (5Y) 4.92
PE TTM —
TSR TTM (38.58%)
Mkt cap US$521.0M
ROIC (18.93%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$4.63
(2.76%)
(89.85%)
Sell 3|3|3|2|12
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.09
0.09
0.09
0.09
6.88%
14.88%
3.82%
16.75%
Revenue$M
28.81
29.85
30.32
31.68
14.93%
16.39%
11.70%
11.61%
Peers (US$521.0M)
Cap (US$)
PE
506.5M
—
Capital
TTM
5Y
10Y
Leveragex
0.786
0.253
0.249
EBIT/Intx
1.531
0.088
0.094
Own earn%
(136.27)
1.64
1.72
Sh yield%
25.02
54.42
51.44
Owners
Insiders/Inst%
11.46
60.37
Short interest%
5.27
SBC / revenue%
1.56
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
13–19
$1 testx
0.6
Incr. ROIC%
0